Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)

被引：3

作者：

Bekaii-Saab, T. S.

Bendell, J. C.

Cohn, A. L.

Hurwitz, H.

Kozloff, M.

Roach, N.

Tezcan, H.

Feng, S.

Sing, A.

Grothey, A.

机构：

[1] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Rocky Mt Canc Ctr, Denver, CO USA

[4] Duke Univ, Med Ctr, Durham, NC USA

[5] Ingalls Hosp, Harvey, IL USA

[6] Univ Chicago, Harvey, IL USA

[7] C3, Alexandria, VA USA

[8] North Idaho Canc Ctr, Coeur Dalene, ID USA

[9] Genentech Inc, San Francisco, CA 94080 USA

[10] Mayo Clin, Coll Med, Rochester, MN USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.3595

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3595

引用

页数：2